The AdvisorShares Pure US Cannabis ETF (MSOS) has swung dramatically over the past year, trading between roughly $2.96 and $7.25. After rallying sharply earlier in 2026 on cannabis reform optimism, the fund has pulled back toward the mid-to-high $4 range, leaving investors to debate whether the next leg higher is realistic. A move to $6.00 would represent a meaningful recovery from current levels without requiring a full retest of the 52-week high, making it a natural psychological milestone and a widely discussed price objective.
MSOS is an actively managed exchange-traded fund (ETF) that invests at least 80% of its net assets in securities of U.S. cannabis and hemp companies, plus derivatives with similar economic characteristics. Because many U.S. cannabis operators trade over-the-counter (OTC) rather than on major U.S. exchanges, the fund relies heavily on total return swaps to gain exposure. This structure lets the ETF track a handful of leading multi-state operators, but it also introduces counterparty and liquidity considerations that ordinary equity ETFs do not carry.
The fund's returns are overwhelmingly driven by a few large positions. Its biggest exposures have historically centered on Trulieve Cannabis (TRLV), Curaleaf (CURLF), and Green Thumb Industries (GTBIF), which together have at times represented a substantial majority of the portfolio. This concentration cuts both ways: when these names rally on reform headlines, the ETF can move sharply, but when sentiment fades, the downside is equally pronounced. The recent NYSE uplisting of Trulieve under the ticker TRLV has been viewed as a milestone for the sector's path toward broader institutional ownership.
The central catalyst is the ongoing effort to reschedule cannabis from Schedule I to Schedule III under U.S. federal law. A 2026 move placing state-licensed medical cannabis into Schedule III removed the burden of Section 280E, which had prevented cannabis operators from deducting ordinary business expenses such as rent, payroll, and interest. Broadening that relief to adult-use operators would materially improve profitability, cash flow, and access to banking and capital across the industry. Analysts and technical forecasts have framed the high-$5 to $6 zone as a realistic upside scenario if rescheduling momentum continues, with some commentary noting the ETF has historically traded at higher sales multiples during periods of elevated reform expectations.
Several structural risks stand in the way of a sustained advance. First, the regulatory process has no firm deadline, and a rescheduling order can face administrative hearings and legal challenges that stretch timelines for months or years. Second, MSOS's extreme concentration in three or four operators means a company-specific setback can disproportionately weigh on the entire fund. Third, the ETF's swap-based structure and the illiquidity of many underlying OTC securities amplify volatility. Finally, much of the sector's near-term optimism has at times appeared priced in, leaving the fund vulnerable to sharp reversals when headlines disappoint.
From a technical perspective, the fund's 52-week range of roughly $2.96 to $7.25 frames the picture. The lower end of that range has acted as a key support zone, while the $7.25 level marks the most recent major high and a clear supply area. Between the current price near $4.80 and the $6.00 target, the ETF would need to clear successive resistance zones, with the psychological $5 level representing an important intermediate hurdle. A sustained breakout above $5, confirmed by constructive price action, would strengthen the case that $6 is reachable.
Traders monitoring volatile, headline-sensitive funds like MSOS may benefit from automated tools that track changing conditions in real time. Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. These signals can help traders discover emerging opportunities, monitor existing positions, and identify changing market trends more efficiently than manual scanning. For those seeking an edge in fast-moving sectors, exploring the platform's signal-driven approach may be worth considering.
Whether MSOS reaches $6 ultimately hinges on regulatory execution more than technical momentum. The strongest case rests on federal rescheduling and the associated tax relief that would transform the earnings power of the fund's largest holdings. The principal risks are the open-ended nature of that process, the fund's heavy concentration, and its tendency toward sharp volatility. Investors should watch for concrete progress on broader rescheduling, further exchange uplistings of major operators, and whether the ETF can reclaim and hold the $5 level. A move to $6 is realistic under a favorable reform scenario, but it is far from assured.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MSOS has been closely correlated with CNBS. These tickers have moved in lockstep 99% of the time. This A.I.-generated data suggests there is a high statistical probability that if MSOS jumps, then CNBS could also see price increases.
| Ticker / NAME | Correlation To MSOS | 1D Price Change % | ||
|---|---|---|---|---|
| MSOS | 100% | +3.23% | ||
| CNBS - MSOS | 99% Closely correlated | +1.93% | ||
| WEED - MSOS | 98% Closely correlated | +2.17% | ||
| MJ - MSOS | 93% Closely correlated | -0.12% | ||
| YOLO - MSOS | 90% Closely correlated | +1.32% | ||
| PRNT - MSOS | 24% Poorly correlated | -0.32% | ||
More | ||||